CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...